Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients

PURPOSE: Glioblastoma is a deadly brain cancer with a median survival time of ∼15 months. Ionizing radiation plus the DNA alkylator temozolomide (TMZ) is the current standard therapy. PAC-1, a procaspase-3 activating small molecule, is blood-brain barrier penetrant and has previously demonstrated ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Avadhut D., Botham, Rachel C., Schlein, Lisa J., Roth, Howard S., Mangraviti, Antonella, Borodovsky, Alexandra, Tyler, Betty, Joslyn, Steve, Looper, Jayme S., Podell, Michael, Fan, Timothy M., Hergenrother, Paul J., Riggins, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655184/
https://www.ncbi.nlm.nih.gov/pubmed/29113289
http://dx.doi.org/10.18632/oncotarget.19085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655184/
https://www.ncbi.nlm.nih.gov/pubmed/29113289
http://dx.doi.org/10.18632/oncotarget.19085

Ejemplares similares